

Application No. 09/730,379
Filing Date: December 5, 2000
Docket: 955-7P/CON
Page 2 of 6

REMARKS

No amendments to the claims have been made as a result of this amendment. Accordingly, claims 2, 3, 36-45 are currently pending.

Applicants wish to thank Examiner Yu for the courtesy of a telephone interview on November 20, 2003 with applicants' representatives, Irving N. Feit and the undersigned.

In the Office Action, claims 2, 3 36-45 were rejected under 35 U.S.C. §112, first paragraph allegedly for lack of enablement. The examiner states that to obviate the rejection, "applicant is requested to point out in the specification which specific disease could be treated by inhibiting thrombospondin binding protein (TSP) and any *in vivo* model."

Applicants advised Examiner Yu that the specification at page 6 discloses the treatment of cardiovascular disease and wound healing in accordance with the claimed invention. Also, applicants wish to point out to the examiner that other conditions are further disclosed in the specification (see last paragraph of page 17).

The examiner then inquired whether there was any working *in vivo* examples demonstrating efficacy of the claimed compositions. Applicants responded by directing the examiner's attention to the *in vivo* experiment at the bottom of page 48 to page 49 of the specification. There, the specification discloses two *in vivo* models demonstrating that histidine-rich glycoprotein (HRGP) inhibits the anti-angiogenic effect of TSP in mice.

The examiner indicated during the telephone interview that, in her opinion, the *in vivo* experiments disclosed in the specification were insufficient to obviate the rejection. The *in vivo* experiments demonstrated inhibition of the anti-angiogenic effect of TSP by HRGP. The examiner contends that demonstration of inhibition of the anti-angiogenic effect of TSP by HRGP does not necessarily mean that the composition is useful for treating a disease or